Aligos Therapeutics Q4 2023 GAAP EPS $(0.22) Beats $(0.27) Estimate, Sales $2.009M Beat $1.600M Estimate
Author: Benzinga Newsdesk | March 12, 2024 04:26pm
Aligos Therapeutics (NASDAQ:
ALGS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. The company reported quarterly sales of $2.009 million which beat the analyst consensus estimate of $1.600 million by 25.56 percent. This is a 43.20 percent decrease over sales of $3.537 million the same period last year.
Posted In: ALGS